ArticleBritish journal of cancer2026
Oligometastatic neuroendocrine tumors: characteristics and prognosis.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oligometastatic neuroendocrine tumours: imprecision is not equivalence.British journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOligometastatic disease (OMD) in neuroendocrine tumors (NET) has hardly been investigated so far and it is unclear how OMD should influence treatment decisions.
methodsThe primary objective of this retrospective analysis was to evaluate characteristics and prognosis of the OMD state in patients with NET G1/G2 of gastroenteropancreatic origin.
resultsThe overall study cohort comprised 190 patients. OMD occurred in 29% of patients (n = 55), 58% of those (n = 32) had synchronous oligometastases. Oligometastases were limited to one organ in most patients (95%) and primarily involved the liver (83% or n = 43/52). Median overall survival (OS) from diagnosis was 117.5 months (95% CI 102.4-149.1 months). Calculated from first metastasis, median OS was 102.4 months (95% CI 98.3-117.5 months) and not significantly longer in oligometastatic patients (117.5 months) versus polymetastatic patients (100.2 months). Locoregional treatment of oligometastases was performed in 24/55 patients (44%) and showed a non-significant trend towards superior survival compared to no such treatment (125.4 versus 99.7 months).
conclusionsThese results suggest that a low absolute number of metastases alone may not be a clear prognostic factor in NET. It remains unknown if locoregional therapies can achieve long-term disease-free survival in a significant number of oligometastatic NET patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.